[Medico-economical assessment in cancerology].
In recent studies, the economic criteria has begun to be integrated to the appraisal in cancerology. The question asked by the economist can be framed as follows: what incremental cost should the collectivity or the health insurance system consent, in order to improve the care of cancer patients? This involves first that the cost of the strategies, foreseen or already implemented, can be appraised, then, that indicators can be defined to capture health improvement, and finally, that this health improvement can be quantified. In this article, we present the process of integrated appraisal (cost/result approach). We specifically analyze costs in cancerology, their source and their evolution. We demonstrate the meaning of the integration of economic costs and medical results. We emphasize on the fact that part of the costs, especially those supported by the patient and his close relations, are most of the time excluded from the analysis. Two main points should be carefully analyzed, when proceeding to an appraisal in cancerology: the measurement of the patient's QoL, which represents an expression of the results of the strategy of care; the financing modalities, for the same type of care, if we consider the specificity of the structures involved and the organization of the care. We conclude by mentioning how difficult this task is and under which conditions it should be developed.
Lebrun
T
T
CRESGE, Université catholique de Lille, France.
Selke
B
B
Bercez
C
C
Bonneterre
M E
ME
Lenne
X
X
Sailly
J C
JC
Bonneterre
J
J
D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005069:Evaluation Studies as Topic; D005602:France; D006801:Humans; D009369:Neoplasms / Q000191:economics* / Q000628:therapy; D010166:Palliative Care; D011788:Quality of Life